Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30

$0.83−0.07 (-8.12%)

Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%

Allogene Therapeutics statistics

70 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 11, 2027 (estimated, during market hours)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 12, 2026

Valuation ratiosIndustry

Market Cap: $285.72M; $280.48M
Enterprise Value: -$103.18M; $148.62M
PB Ratio: 0.73; 2.05
P/TBV Ratio: 0.73; 2.29

Share statisticsIndustry

Shares Outstanding: 345M; 58M
Shares Change (YoY): 31.6%; 10.9%
Shares Change (QoQ): 0.27%; 0.48%
Float: 294M; 49M
Shares Held by Insiders: 15.0%; 12.1%
Shares Held by Institutions: 90.5%; 56.4%

Short sellingIndustry

Short Interest: 51M; –
Short Interest Change: -3.97%; -0.76%
Short % of Float: 17.5%; 9.06%
Short % of Shares Outstanding: 14.8%; 6.30%
Days to Cover: 6.20; 5.13

Stock price statisticsIndustry

52-Week High: $4.46; –
52-Week Low: $0.82; –
20-Day Moving Average: $1.16; –
50-Day Moving Average: $1.43; –
200-Day Moving Average: $1.95; –
Average True Range (14): $0.10; –
Price Change (1 Week): -24.1%; 1.51%
Price Change (1 Month): -36.4%; -2.37%
Price Change (3 Months): -59.7%; -21.1%
Price Change (6 Months): -61.4%; -22.8%
Price Change (YTD): -39.6%; -22.6%
Price Change (1 Year): -33.3%; -21.0%
Price Change (3 Years): -65.8%; -24.8%
Price Change (5 Years): -95.7%; -76.9%
Average Volume (10 Days): 14M; –
Average Volume (20 Days): 11M; –
Average Volume (90 Days): 7M; –
Relative Volume: 1.53; 0.80
Relative Strength Index (14): 22.2; 44.7
Volatility (1 Year): 83.7%; 80.2%
Beta (5 Years): 1.61; 1.07

Returns on capitalIndustry

Return on Equity (ROE): -49.3%; -51.3%
Return on Assets (ROA): -36.7%; -40.7%
Return on Invested Capital (ROIC): -717.6%; -32.9%
Return on Capital Employed (ROCE): -40.2%; -38.1%

Financial positionIndustry

Current Ratio: 7.79; 3.31
Quick Ratio: 10.10; 2.41
Interest Coverage: -142.48; -6.35

EfficiencyIndustry

Profits Per Employee: -$1.15M; -$683.67K
Employee Count: 152; 75
WACC: 12.9%; 10.0%

Income statement (TTM)Industry

Operating Income: -$190.21M; -$20.99M
Net Income: -$174.46M; -$21.61M
EBITDA: -$179.05M; -$16.85M
EPS (Diluted): -$0.63; -$0.75

Balance sheetIndustry

Cash & Short-Term Investments: $388.90M; $67.18M
Net Cash (Debt): $388.90M; $16.98M
Net Cash Per Share: $1.13; $0.72
Equity (Book Value): $392.55M; $52.68M
Book Value Per Share: $1.14; $1.50
Tangible Book Value: $392.55M; $26.74M
Working Capital: $261.33M; $78.52M

Cash flow (TTM)Industry

Operating Cash Flow: -$108.63M; -$12.27M
Capital Expenditures: -$184.00K; -$944.00K
Free Cash Flow: -$108.81M; -$18.20M
FCF Per Share: -$0.31; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -61.1%; -21.0%
FCF Yield: -38.1%; -9.44%
Dividend Yield: 0.00%; 1.88%
Shareholder Yield: 0.00%; 0.00%
Dividend Per Share: $0.00; $0.83
Years of Dividend Growth: 0; 0

Taxes and interestIndustry

Interest Expense: $1.34M; $2.97M

Scores and fair valueIndustry

Altman Z-Score: -5.05; 0.26
Piotroski F-Score: 3; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	ALLO	S&P 500	Difference	ALLO per year	S&P 500 per year
1 month	-40.9%	-2.7%	−38.2 pts
3 months	-60.0%	-1.7%	−58.3 pts
Year to date	-39.6%	+11.9%	−51.5 pts
1 year	-32.8%	+12.0%	−44.7 pts
3 years	-66.9%	+78.2%	−145.1 pts	-30.8%	+21.2%
5 years	-95.7%	+73.2%	−168.9 pts	-46.7%	+11.6%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

51M ALLO shares were sold short on Oct 30, 2026, down 4.0% from the previous report, or 17.47% of the shares available to trade. At recent volumes it would take 6.2 days to buy them back. Over the last 20 sessions, 31.4% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	51,285,271	-4.0%	8,270,990	6.2
Oct 15, 2026	53,405,256	-4.0%	5,775,784	9.3
Sep 30, 2026	55,606,815	-6.7%	6,181,659	9.0
Sep 15, 2026	59,600,117	+0.8%	5,295,103	11.3
Aug 31, 2026	59,114,784	+0.3%	4,866,047	12.2
Aug 14, 2026	58,945,687	-3.0%	4,941,400	11.9
Jul 31, 2026	60,753,788	+1.7%	6,581,334	9.2
Jul 15, 2026	59,712,398	-5.8%	9,403,966	6.3
Jun 30, 2026	63,385,047	+32.0%	12,327,603	5.1
Jun 15, 2026	48,035,062	+8.0%	7,735,975	6.2
May 29, 2026	44,480,150	+5.2%	6,566,258	6.8
May 15, 2026	42,275,161	+14.7%	6,595,129	6.4

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Allogene Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALLO.

Compare: ALLO vs SNTI · ALLO vs LYEL · ALLO vs INMB · ALLO vs ARTV · ALLO vs AIM

Revenue growth-100.0% · median -41.1%

Company	Revenue	Growth
AIM	$91.00K	-18.8%
LYEL	$15.00K	-63.4%
ALLO	$0	-100.0%
SNTI	–	–
INMB	–	–
ARTV	–	–

Company

Next earnings (est.): Mar 11, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 152
Held by institutions: 90.5%
Auditor: Ernst & Young LLP
SEC CIK: 1737287

Advertisement
300 × 250

See a number that looks wrong?